Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Study Published year Study type No. of cases Endpoints Treatment regimen Radiation dose (Gy) Endostatin usage Total duration of endostatin
Jiang [16] 2012 Prospective cohort study 25 1-, 2-yr OS rate, 1-, 2-yr LCR, OS, ORR, AEs ERT 60 15 mg/day IV for 7 days during the first week of RT 7 days× 1 cycles
Zhai [18] 2019 Single-arm prospective study 67 1-, 2-, 3-yr PFS/OS rate, PFS,OS, ORR, AEs ECRT 60–66 7.5 mg/m2/day CIV for 5 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT 5 days× 4 cycles
Sun [21] 2016 Single-arm prospective study 19 ORR, PFS, OS, AEs ECRT 60–66 7.5 mg/m2/day IV for 14 days per 3 weeks during RT 14 days× 2 cycles
Bao [22] 2015 Single-arm prospective study 48 OS, 1-, 2-, 3-yr PFS/OS rate and LCR, PFS, ORR, AEs ECRT 60–66 7.5 mg/m2/day IV for 7 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT 7 day× 4 cycles
Tang [23] 2016 Single-arm retrospective study 78 PFS, OS, ORR ECRT 60–66 7.5 mg/m2/day IV over 4 h per day for 7 days, or CIV for 5 days, at week 1, 3, 5 and 7, endostatin administrated 1 week prior to CRT 5/7 days× 4 cycles
Wen [24] 2009 Prospective cohort study 14 ORR, PFS, 1-yr OS rate ERT 66–68 15 mg/day IV during the first three weeks of RT 21 days× 1 cycles
Chen [25] 2017 Prospective cohort study 20 ORR, PFS, OS, AEs ERT 60–66 15 mg/day IV for 14 days per three weeks during RT 14 day×2 cycles
  1. OS Overall survival, PFS Progression-free survival, ORR Objective response rate, LCR Local control rate, AEs Adverse events, ERT Endostatin combined with radiotherapy, ECRT Endostatin combined with concurrent chemoradiotherapy, yr Year, RT Radiotherapy, IV Intravenous injection, CIV Continuous intravenous pumping